June 8, 2016

Brammer Bio Establishes Dedicated Late Phase Development and Commercial Manufacturing Facility for Advanced Cell and GeneTherapies in Lexington, Mass.

Brammer Bio, the best-in-class cell and gene therapy contract development and manufacturing organization, is proud to announce plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The facility will be qualified and operational by Q2 of 2017 in Lexington, MA.

Read the Press Release here.


Brammer Bio President & CEO Mark Bamforth announces plans for a new manufacturing facility in Lexington at the BIO International Convention in San Francisco.